ArticleEClinicalMedicine2023
Change in body weight and risk of hypertension after switching from efavirenz to dolutegravir in adults living with HIV: evidence from routine care in Johannesburg, South Africa.
Article in EClinicalMedicine, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 70 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
70 citing papers in PubMed, 96 citations in OpenAlex.
- Cardiometabolic impact of dolutegravir as second-line therapy: secondary analysis of a randomized controlled trial.AIDS (London, England) · 2026Trial
- Initiation of dolutegravir vs efavirenz on 12- and 24-month weight, body mass index, blood pressure, and incident hypertension: A target trial emulation.Annals of epidemiology · 2026Trial
- Incident hypertension among adults on ART in Malawi: a nested cohort study.BMC infectious diseases · 2025Trial
- Non-communicable disease (NCD) risk among people living with HIV in KwaZulu-Natal, South Africa: evidence from a randomised trial of community-based differentiated service delivery.Journal of the International AIDS Society · 2025Trial
- Change in Blood Pressure, Weight, and Other Cardiovascular Disease Risk Factors After Switch From Protease Inhibitors to Dolutegravir: Post hoc Analysis of the 48-week Randomised Second-line Switch to Dolutegravir Trial.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2025Trial
- Trial
- Development and feasibility testing of a time-restricted eating intervention for women living with overweight/obesity and HIV in a resource-limited setting of South Africa.BMC public health · 2024Trial
- Blood pressure increases are associated with weight gain and not antiretroviral regimen or kidney function: a secondary analysis from the ADVANCE trial in South Africa.Journal of the International AIDS Society · 2024Trial
- Weight Changes and Adverse Pregnancy Outcomes With Dolutegravir- and Tenofovir Alafenamide Fumarate-Containing Antiretroviral Treatment Regimens During Pregnancy and Postpartum.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2024Trial
- A Phase-IV Non-interventional Study to Assess Virological Effectiveness, Safety, and Tolerability of DTG-based Antiretroviral Therapy in HIV-1 Infected Indian Persons Living with HIV.Current HIV research · 2024Trial
- Metformin for the prevention of diabetes among people with HIV and either impaired fasting glucose or impaired glucose tolerance (prediabetes) in Tanzania: a Phase II randomised placebo-controlled trial.Diabetologia · 2023 · on this mapTrial
- Risk of Major Adverse Cardiovascular Events With Dolutegravir Versus Efavirenz-Based Antiretroviral Therapy: Emulated Target Trials Using Routine, De-identified Data From South Africa.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2026Article
- Factors associated with prevalent hypertension among adults living with HIV receiving antiretroviral therapy in Yaounde, Cameroon: a cross-sectional study.AIDS research and therapy · 2026Article
- Effect of dolutegravir-based antiretroviral therapy transition on body mass index in adolescents living with HIV: secondary analysis of data from the ANRS 12225 Pediacam III cohort in Cameroon.AIDS research and therapy · 2026Article
- Risk of obesity, diabetes, hypertension, and major adverse cardiovascular events after a switch to an integrase inhibitor: a target trial emulation in REPRIEVE.The lancet. HIV · 2026Article
- Article
- Longitudinal Blood Pressure Trajectory and Subclinical Echocardiographic Measures of Cardiovascular Disease in People Living With HIV: A Comparative Prospective Cohort Study.Journal of the American Heart Association · 2026Article
- Evaluation of the relevance, acceptability, and adaptability of an existing healthy lifestyle program for people living with HIV.BMC public health · 2026Article
- Prevalence and determinants of cardiometabolic comorbidities among people living with HIV receiving antiretroviral therapy at Zewditu Memorial Hospital: evidence from Ethiopia's longest serving AIDS clinic.BMC infectious diseases · 2026Article
- Article
10 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 2 institutions in 2 countries.
Funding
Abstract
Background: The integrase strand transfer inhibitor (INSTI) dolutegravir is recommended in World Health Organization guidelines, but is associated with weight gain. We evaluated weight change in patients switching from efavirenz to dolutegravir in first-line antiretroviral therapy (ART) in Johannesburg, South Africa. Methods: We conducted a prospective cohort study of adults (≥16 years) of black African ancestry with HIV who initiated ART between January 2010-December 2020. Patients were propensity score-matched 1:1 (unexposed i.e. remaining on efavirenz: exposed i.e. switched from efavirenz to dolutegravir) on sex, age, months on ART, first ART regimen, haemoglobin, body mass index (BMI), blood pressure, viral load and CD4 count. We used linear regression to assess the effect of switching from efavirenz to dolutegravir on weight change and hypertension 12 months after exposure. Findings: We matched 794 patients switching to dolutegravir to 794 remaining on efavirenz. Exposed patients had a higher mean change in weight (1.78 kg; 95% confidence interval (CI):1.04,2.52 kg) from start of follow-up to 12 months vs. unexposed. We also found a 14.2 percentage point increase (95% CI: 10.6,17.7) in the risk of hypertension in those exposed to dolutegravir vs those that remained on efavirenz. Interpretation: In a real-world population, patients gained more weight and were at higher risk of hypertension after switching from efavirenz to dolutegravir than those remaining on efavirenz. Longer follow-up is needed, however, to determine if INSTI-associated weight gain is associated with changes in non-communicable disease risk over the long-term, or whether weight gain is sustained, as seen in clinical trials. Funding: This study has been made possible by the generous support of the American People and the President's Emergency Plan for AIDS Relief (PEPFAR) through the United States Agency for International Development (USAID), under the terms of cooperative agreement cooperative Agreement 72067419CA00004. In addition to the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) 1K01MH105320-01A1.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.